Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Capucine Baldini is active.

Publication


Featured researches published by Capucine Baldini.


Journal of Oncology Practice | 2018

What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper

Kah Poh Loh; Enrique Soto-Perez-de-Celis; Tina Hsu; Nienke A. de Glas; Nicolò Matteo Luca Battisti; Capucine Baldini; Manuel Rodrigues; Stuart M. Lichtman; Hans Wildiers

Aging is a heterogeneous process. Most newly diagnosed cancers occur in older adults, and it is important to understand a patients underlying health status when making treatment decisions. A geriatric assessment provides a detailed evaluation of medical, psychosocial, and functional problems in older patients with cancer. Specifically, it can identify areas of vulnerability, predict survival and toxicity, assist in clinical treatment decisions, and guide interventions in routine oncology practice; however, the uptake is hampered by limitations in both time and resources, as well as by a lack of expert interpretation. In this review, we describe the utility of geriatric assessment by using an illustrative case and provide a practical approach to geriatric assessment in oncology.


Anti-Cancer Drugs | 2017

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

Lina Benajiba; Jean-Marie Michot; Capucine Baldini; Laura Faivre; Andrea Varga; Rastilav Balheda; Anas Gazzah; Ecaterina Ileana; Sophie Postel-Vinay; Christophe Massard; Stéphane de Botton; Jean-Charles Soria; Vincent Ribrag

Despite considerable progress in hematological malignancies (HM) biology during the last decades, translation into clinical benefit remains a major challenge. To improve patient selection and identify patients most likely to benefit from phase I trials, we designed and validated, in an independent cohort, a simple prognostic score. Treatment outcome, toxicity, and survival data from 82 consecutive patients enrolled in 14 phase I trials were reviewed (January 2008–February 2012). We validated these results on a prospectively collected cohort (17 phase I trials, February 2012–May 2014, 88 patients). Within a median follow-up of 19.1 months (range: 2.1–43.8 months), the median progression-free and overall survival (OS) were, respectively, 4.1 months [95% confidence interval (CI): 3.0–5.3] and 19.8 months (95% CI: 16.1–36.8). Best overall response and disease control rates were similar to HM salvage regimens (28 and 64%, respectively). Through multivariate analysis of independent prognostic factors, we designed and prospectively validated a simple prognostic score based on histological subtype, performance status, and albumin. Patients with a low-risk score experienced significantly better OS compared with patients with an intermediate or a high score (median OS: 37 vs. 17 vs. 5 months; hazard ratio=11.68, 95% CI: 4.09–33.3). Our data indicate the safety and efficacy of phase I trials in a significant number of relapsed/refractory HM patients, with clinical benefit achieved in more than half of patients. Our simple scoring system offers a valuable selection tool encouraging HM patient inclusions in phase I trials.


Oncotarget | 2018

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

Luc Cabel; Alina Fuerea; Ludovic Lacroix; Capucine Baldini; Patricia Martin; Antoine Hollebecque; Sophie Postel-Vinay; Andrea Varga; Rastilav Balheda; Anas Gazzah; Jean-Marie Michot; Aurélien Marabelle; Etienne Rouleau; Eric Solary; Thierry de Baere; Eric Angevin; Jean-Pierre Armand; Stefan Michiels; Jean-Yves Scoazec; Samy Ammari; Fabrice Andre; Jean-Charles Soria; Christophe Massard; Loic Verlingue

A targeted therapy is recommended in case of ERBB2 alteration for breast and gastric carcinomas, but miscellaneous other tumor types are ERBB2-altered at low prevalence. Broadening the administration of HER2 inhibitors across tumor types and genomic alterations could benefit to patients with refractory metastatic tumors. Targeted next-generation-sequencing (tNGS) and comparative genomic hybridization array (CGH) have been performed on fresh tumor biopsies of patients included in the MOSCATO-01 and ongoing MOSCATO-02 trials to administrate HER2 inhibitors in case of ERBB2 pathogenic mutation of amplification. Between December 2011 and January 2017 a molecular analysis was performed for 934 patients (759 CGH and 912 tNGS). A novel ERBB2 alteration has been found in 4.7% (n = 44/934), including 1.5% (n = 14/912) ERBB2 mutations, and 4% (n = 30/759) ERBB2 amplifications. A matched HER2 inhibitor was administrated to 70% (31/44) of patients and consisted in trastuzumab plus chemotherapy for 90% of them (28/31). On the 31 evaluable patients, 1 complete response (CR), 10 partial response (PR) and 2 stable disease (SD) >24 weeks were observed accounting for a clinical benefit rate (CBR) of 42% (n = 13/31, 95% CI 25–61%). Besides breast and oesogastric carcinomas, 19 patients affected by 8 different tumor types had a CBR of 25% for ERBB2 mutations (n = 2/8, 95% CI 3%–65%, with 2 PR) and 64% for ERBB2 amplifications (n = 7/11, 95% CI 31%–89%; with 1 CR, 4 PR, 2 SD). ERBB2 genomic alterations were diffuse across metastatic tumor types and signs of efficacy emerged for HER2 targeted treatments, especially in case of ERBB2 amplifications or a p.S310Y ERBB2 mutation.


Journal of Geriatric Oncology | 2018

Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper

E. Bastiaannet; Nicolò Matteo Luca Battisti; Kah Poh Loh; Nienke A. de Glas; Enrique Soto-Perez-de-Celis; Capucine Baldini; Ellen Kapiteijn; Stuart M. Lichtman

Malignant melanoma is an aggressive cancer associated with a poor prognosis in patients with metastatic disease. As in many other cancers, the incidence of melanoma rises with age; and combined with the longer life expectancy, this led to an increasing prevalence of melanoma in the older population. Recently, immune checkpoint inhibitors significantly improved the treatment of melanoma given their efficacy and tolerability profile. Two major classes of agents include the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors, such as ipilimumab, and the anti-programmed death-ligand 1 (PD-1) inhibitors, such as nivolumab and pembrolizumab. Treatment of metastatic disease with immune checkpoint inhibitors demonstrated improved efficacy and better safety profiles compared to cytotoxic drugs and appears to be an attractive treatment option. Nevertheless, there is a need for tools designed to better predict which older patients will benefit from its use and who will experience toxicities related to the treatment. Current data do not show a major increase in toxicity rates in older patients. However, patients above 75 are often under-represented and those who are included are not representative of the general population of older patients, thereby also stressing the need for real-life data. Ongoing research is aiming at maximizing the potential treatment efficacy and developing novel immune-targeting modalities. Future studies should include older patients and assess geriatric domains in these older patients to better guide decision-making. This review discusses published clinical trials and where known, the efficacy and toxicity in older patients. Moreover, the clinical implications and future perspectives are discussed, with current recommendations for older patients, management of toxicities, and a proposal for an initial approach to the treatment of older patients with metastatic melanoma.


Investigational New Drugs | 2018

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

Jean-Marie Michot; Lina Benajiba; Laura Faivre; Capucine Baldini; Lelia Haddag; Clément Bonnet; C. Massard; Frederic Bigot; Camille Bigenwald; Benjamin Verret; Zoé A. P. Thomas; Andrea Varga; Anas Gazzah; Antoine Hollebecque; David Ghez; Julien Lazarovici; Rastilav Balheda; Aurore Jeanson; Sophie Postel-Vinay; Alina Danu; Jean-Charles Soria; Xavier Paoletti; Vincent Ribrag

SummaryBackground Although safety and prognostic factors for overall survival (OS) have been extensively studied in Phase I clinical trials on patients with solid tumours, data on lymphoma trials are scarce. Here, we investigated safety, outcomes and prognostic factors in relapsed or refractory lymphoma patients included in a series of Phase I trials. Method and patients All consecutive adult patients with recurrent/refractory lymphoma enrolled in 26 Phase I trials at a single cancer centre in France between January 2008 and June 2016 were retrospectively assessed. Results 133 patients (males: 65%) were included in the analysis. The median (range) age was 65 (23–86). Aggressive non-Hodgkin, indolent non-Hodgkin and Hodgkin types accounted for 64%, 25% and 11% of the patients, respectively. The patients had received a median (range) of 3 (1–13) lines of treatment prior to trial entry. The median [95% confidence interval] progression-free survival and OS times were 3.0 [1.8–3.6] and 17.8 [12.7–30.4] months, respectively. High-grade toxicity (grade 3 or higher, according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events classification) was experienced by 56 of the 133 patients (42%) and was related to the investigational drug in 44 of these cases (79%). No toxicity-related deaths occurred. Dose-limiting toxicity (DLT) was encountered in 11 (9%) of the 116 evaluable patients. High-grade toxicity occurred during the DLT period for 34 of the 56 patients (61%) and after the DLT period in the remaining 22 (39%). The main prognostic factors for poor OS were the histological type (i.e. tumour aggressiveness), an elevated serum LDH level, and a low serum albumin level. Early withdrawal from a trial was correlated with the performance status score, the histological type and the serum LDH level. The overall objective response and disease control rates were 24% and 57%, respectively. Conclusion Performance status, LDH, albumin and histological type (tumour aggressiveness) appear to be the most relevant prognostic factors for enrolling Phase I participants with relapsed or refractory lymphoma. 39% of the patients experienced a first high-grade toxic event after the dose-limiting toxicity period, suggesting that the conventional concept of dose-limiting toxicity (designed for chemotherapy) should be redefined in the era of modern cancer therapies.


Expert Opinion on Investigational Drugs | 2018

Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives

Enrique Soto-Perez-de-Celis; Kah Poh Loh; Capucine Baldini; Nicolò Matteo Luca Battisti; Yanin Chavarri-Guerra; Nienke A. de Glas; Tina Hsu; Arti Hurria

ABSTRACT Introduction: One-third of breast cancer (BC) cases worldwide occur in women aged 65 years and older, with 10 to 15% overexpressing the human epidermal growth factor receptor 2 (HER2). Although several HER2-targeted therapies have been developed, the lack of data regarding their use in older patients hampers evidence-based decision-making for this population. Areas Covered: We review current evidence on the efficacy and safety of HER2-targeted therapies in older adults with BC, focusing on approved therapies such as trastuzumab, lapatinib, pertuzumab, ado-trastuzumab-emtansine, and neratinib. Additionally, we discuss drugs under development to target the HER2-receptor, and to overcome resistance to existing therapies. Finally, we highlight the cardiotoxicity of HER2-targeted drugs among older adults. Expert Opinion: Older adults are underrepresented in trials of HER2-targeted therapies in BC. We propose strategies to increase recruitment of older adults in clinical trials in order to increase the evidence base to treat this growing population.


British Journal of Cancer | 2018

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Sarah Watson; Jessica Menis; Capucine Baldini; Patricia Martin-Romano; Jean-Marie Michot; Antoine Hollebecque; Jean-Pierre Armand; C. Massard; Jean-Charles Soria; Sophie Postel-Vinay; Xavier Paoletti

BackgroundReliable evaluation of treatment benefit in early phase clinical trials is necessary. The time to progression ratio (TTPr), which compares successive TTP in a single patient, is a powerful criteria for determining targeted or immune therapies efficacy.MethodsWe evaluated 205 TTPr in a large cohort of 177 advanced cancer patients enrolled in at least two Phase 1/1b trials (out of 2827 phase 1/1b-treated patients) at Gustave Roussy.ResultsThis first wide description of TTPr showed that, under the hypothesis of overall absence of treatment line effect, the median TTPr was 0.7 and that 25% of patients presented a TTPr above the conventional efficacy threshold of 1.3.ConclusionsA higher median TTPr and a larger proportion of patients above the 1.3 threshold should therefore be achieved to conclude to drug efficacy. New guidelines for TTPr interpretation and calibration are proposed, which warrant independent prospective validation.


Journal of Geriatric Oncology | 2017

Are phase I trials safe for older patients

Capucine Baldini; Olivia Le Saux; Sandrine Aspeslagh; Eduardo Castanon; Andrea Varga; Anas Gazzah; Rastilav Bahleda; Olivier Mir; Christophe Massard; Jean-Charles Soria; Antoine Hollebecque

Phase I clinical trials in oncology primarily aim to assess the toxicity profile of new drugs and determine recommended phase II doses (RP2D). Since the cancer rate increases with age and our population is continually aging, RP2D must necessarily be assessed in older patients. Few clinical studies include older patients, however, and particularly few Phase I trials. We reviewed published data on the safety and efficacy of Phase I trials in older patients. The majority of studies included primarily young, fit patients, with age thresholds varying widely from 65 to 80years. However, age does not seem to be associated with more toxicity or less efficacy. While Phase I trials seem feasible in fit older patients, geriatric-medicine score systems should be included in the clinical trial design in order to better characterize this population.


Bulletin Du Cancer | 2012

Mise au point sur l’inhibition de la voie Ras-MAPK : les inhibiteurs de MekFocus on targeting the Ras-MAPK pathway: the Mek inhibitors

Capucine Baldini; Boris Duchemann; Antoine Hollebecque; E. Routier; A. Varga; Anas Gazzah; Rastio Bahleda; Benjamin Besse; Jean-Charles Soria; Christophe Massard

The Ras/Raf/Mek/Erk pathway is a key component of tumor progression and modulates proliferation, survival, differentiation and angiogenesis. Hyperactivation of this pathway is highly implicated in tumorigenesis especially by gain of function mutation of Kras or Braf. Mek position at the end of the pathway seems to be a promising new therapeutic target in the Kras or Braf mutated cancers. In this review, we aimed at describing the Ras/Raf/Mek/Erk pathway, the new therapeutic approaches in solid tumors and their toxicities. However, there seems to be predictives factors of tumor responses to these new agents and mechanisms of resistance that we will tend to analyse.


European Journal of Cancer | 2017

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

Roger Sun; Stéphane Champiat; Laurent Dercle; Sandrine Aspeslagh; Eduardo Castanon; Elaine Johanna Limkin; Capucine Baldini; Sophie Postel-Vinay; Antoine Hollebecque; Christophe Massard; Samy Ammari; Eric Deutsch; Jean-Charles Soria; Aurélien Marabelle; Charles Ferté

Collaboration


Dive into the Capucine Baldini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anas Gazzah

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vincent Ribrag

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Varga

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar

Andrea Varga

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge